We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ablynx Announces Extension of Nanobody Drug Discovery and Development Alliance
News

Ablynx Announces Extension of Nanobody Drug Discovery and Development Alliance

Ablynx Announces Extension of Nanobody Drug Discovery and Development Alliance
News

Ablynx Announces Extension of Nanobody Drug Discovery and Development Alliance

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ablynx Announces Extension of Nanobody Drug Discovery and Development Alliance"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ablynx has announced that its drug discovery and development alliance with Novartis has been extended for another year.

Under the terms of the agreement, entered into in December 2005, the companies are collaborating to discover and develop novel Nanobody® based therapeutics against disease targets that are difficult to address with conventional antibodies or their fragments. Novartis has exclusive right to develop and commercialize the Nanobody® products resulting from the collaboration.

As part of the collaboration Ablynx receives license fees and funding for research and development: these are now extended for a further year. In addition, Ablynx is eligible for milestone payments and royalties upon commercialization.

Edwin Moses, CEO and Chairman of Ablynx, commented: "We are delighted our collaboration with Novartis, one of the leading pharmaceutical companies with a significant track record in innovative drug development, is extended for another year. This is an important partnership for Ablynx and we look forward to progressing our joint efforts to advance the Nanobody®-based programmes to the next stage.

Advertisement